help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH

This version published online on June 11, 2009
Endocrinology, doi:10.1210/en.2009-0216
This Article
Right arrow Author Manuscript (PDF)
Right arrow Supplemental Data
Right arrow All Versions of this Article:
150/9/4012    most recent
Author Manuscript (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Google Scholar
Right arrow Articles by DAVID, V.
Right arrow Articles by ROWE, P. S. N.
PubMed
Right arrow PubMed Citation
Right arrow Articles by DAVID, V.
Right arrow Articles by ROWE, P. S. N.

Submitted on February 20, 2009
Accepted on June 4, 2009

MEPE is a new bone renal hormone & vascularization modulator

Valentin DAVID, Aline MARTIN, Anne-Marie HEDGE, and Peter S. N. ROWE*

The Kidney Institute, Kansas University Medical Center, Kansas City KS, USA

* To whom correspondence should be addressed. E-mail: prowe{at}kumc.edu.

Increased MEPE expression occurs in several phosphate and bone-mineral metabolic disorders. To resolve whether MEPE plays a role we created a murine model over-expressing MEPE protein (MEPE tgn) in bone. MEPE tgn mice displayed a growth and mineralization defect with altered bone-renal vascularization that persisted to adulthood. The growth mineralization defect was due to a decrease in bone remodeling and MEPE tgn mice were resistant to diet induced renal calcification. MEPE-protein derived urinary ASARM-peptides and reduced urinary Ca X PO4 product mediated the suppressed renal calcification. Osteoblastic cells displayed reduced activity but normal differentiation. Osteoclastic precursors were unable to differentiate in the presence of osteoblasts. In the kidney, NPT2a up-regulation induced an increase in phosphate renal reabsorption, leading to hyperphosphatemia. We conclude MEPE and MEPE-PHEX interactions are component to an age-diet dependent pathway that regulates bone turnover, mineralization and suppresses renal calcification. This novel pathway also modulates bone-renal vascularization and bone turnover.


Key words: PHEX • MEPE • DMP1 • ASARM • mineralization • osteomalacia • SIBLING proteins • FGF-23 • X-linked hypophosphatemic rickets • Leptin







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2009 by The Endocrine Society